Tysabri Quick Reference Guide
Generic name
• Natalizumab
Date approved
• November 2004
Manufacturer
• Elan Pharmaceuticals
Status
• Removed 2/2005
Approved uses
• Multiple Sclerosis
Off-label uses
• Crohn’s Disease
Serious side effects
• PML
• Death
What is Tysabri?
Tysabri (Natalizumab) is a humanized monoclonal antibody marketed by Elan Corp and Biogen Idec.
Who takes it, and for what condition?
It is considered a last-resort treatment for multiple sclerosis (MS) and has been approved to treat Crohn’s disease.
How does Tysabri work?
Tysabri is believed to inhibit white blood cells from getting into the brain and attacking nerves, which appears to result in fewer of the brain lesions that cause multiple sclerosis symptoms.
Studies have linked Tysabri to severe liver damage, in some cases within just a few days of the first dose of the drug.
It also can cause a fatal brain disorder called progressive multifocal leukoencephalopathy (PML) and may be linked to the development of melanoma.
What can you do?
If you or someone you love developed PML, liver damage, or any other condition possibly associated with Tysabri, you have valuable legal rights. Please call our toll-free number (1-888-341-1405) to discuss your case with one of our personal injury lawyers.
Trust our Massachusetts products liability attorneys to help
Contact the Boston law firm of Thornton Law Firm LLP online or at 1-888-341-1405 for a free consultation with a recognized leader in Massachusetts defective drug litigation. You have nothing to risk. We offer a fair and accurate assessment of your case.
